STOCK TITAN

BIOLASE LAUNCHES RESEARCH GRANT PORTAL TO ACCELERATE CLINICAL STUDIES ON INNOVATIVE DENTAL LASER TECHNOLOGY

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Rhea-AI Summary

BIOLASE, a leader in dental lasers, has launched a new Research Grant Portal to facilitate the global submission and evaluation of laser research projects. This initiative reflects BIOLASE's 30+ year commitment to enhancing laser technology in dentistry, supported by over 300 patents and numerous published studies. The portal aims to attract research proposals focused on pediatric dentistry, endodontics, and related fields, promoting minimally invasive laser technology and improving patient outcomes.

Positive
  • Launch of Research Grant Portal to expedite research proposal submissions.
  • Over 30 years of leadership in dental laser technology.
  • 302 issued patents and 31 pending patents enhancing innovation.
  • Focus on advancing clinical studies in key dental fields.
Negative
  • None.

New application portal will help advance the submission, evaluation, and acceptance of laser research projects globally

LAKE FOREST, Calif., Oct. 5, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it is inviting clinicians and researchers from around the world to submit research proposals via the Research Grant Portal at biolase.com/researchgrants.

BIOLASE's continued leadership and commitment to research and development in the dental field has been evident for over 30 years, resulting in hundreds of published articles, along with 302 issued and 31 pending patents on its technologies. This new research application portal is designed to help accelerate the submission, evaluation, and acceptance of research projects, while continuing to build upon the strong foundation of clinical evidence supporting BIOLASE laser technology. In particular, BIOLASE is seeking studies in pediatric dentistry, endodontics, periodontics, implantology and photobiomodulation (PBM) to help further the advancement of minimally invasive laser technology in these fields.

"BIOLASE recognizes the importance of clinical research around the continued advancement of dental lasers and adoption of this breakthrough technology," said BIOLASE President and CEO, John Beaver. "Our new Research Grant Portal will allow us to evaluate and accept high-quality research proposals from all over the world and continue to demonstrate how BIOLASE lasers provide biologically and clinically superior performance with a more comfortable patient experience and faster recovery times."

To learn more about the grant application process and research topics of interest, please visit biolase.com/researchgrants.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-launches-research-grant-portal-to-accelerate-clinical-studies-on-innovative-dental-laser-technology-301641128.html

SOURCE BIOLASE, Inc.

FAQ

What is the purpose of the new Research Grant Portal by BIOL?

The Research Grant Portal aims to streamline the submission and evaluation of dental laser research proposals globally.

What types of studies is BIOL seeking through the portal?

BIOL is looking for proposals focused on pediatric dentistry, endodontics, periodontics, implantology, and photobiomodulation.

How long has BIOLASE been a leader in dental laser technology?

BIOLASE has been a leader in dental laser technology for over 30 years.

How many patents does BIOLASE hold in laser technology?

BIOLASE holds 302 issued patents and has 31 pending patents related to its technologies.

BIOLASE INC

OTC:BIOL

BIOL Rankings

BIOL Latest News

BIOL Stock Data

2.39M
33.40M
0.3%
6.56%
5%
Medical Devices
Dental Equipment & Supplies
Link
United States of America
FOOTHILL RANCH